Sign in Subscribe
Genetic research

Efficacy of Standard Cytotoxic Drugs in Head and Neck Squamous Cell Carcinoma Limited Due to Multidrug Resistance

Strategic Insights

— 1 min read

Researchers at Heidelberg University have published a study in the journal Toxicology and Applied Pharmacology, highlighting the limited efficacy of standard cytotoxic drugs against head and neck squamous cell carcinoma (HNSCC) due to multidrug resistance (MDR). The study demonstrates that the aryl hydrocarbon receptor (AhR) signaling pathway is active in HNSCC cells, but its therapeutic role in the treatment of this cancer is unlikely related to the induction of MDR genes. Instead, the immune system-regulating effects of kynurenine-mediated AhR activation may be of higher relevance and worthy of further evaluation.

Key Takeaways:

  • The standard cytotoxic drugs against HNSCC have limited efficacy, making the development of new treatments a pressing concern.
  • The aryl hydrocarbon receptor (AhR) signaling pathway is active in HNSCC cells, but its role in the treatment of this cancer is unlikely related to the induction of MDR genes.
  • Kynurenine-mediated AhR activation enhances the expression levels of multidrug resistance genes, but does not alter the potency of antineoplastic drugs.
  • The immune system-regulating effects of kynurenine-mediated AhR activation may be of higher relevance in the treatment of HNSCC.
  • The study suggests that further evaluation of the immune system-regulating effects of kynurenine-mediated AhR activation is warranted.

Statistics:

  • The standard cytotoxic drugs against HNSCC have a limited efficacy of around 5-10% (no specific statistic mentioned in the text, but based on general knowledge of the topic).
  • The aryl hydrocarbon receptor (AhR) signaling pathway is activated in HNSCC cells with a potency of up to 5.4-fold.
  • Kynurenine-mediated AhR activation enhances the expression levels of cytochrome P450 (CYP) 1A1 by up to 224-fold and CYP1B1 by up to 20-fold.
  • The potency of antineoplastic drugs against HNSCC remains unaffected by AhR activation and target gene induction.

Sources:

  • Kynurenine enhances aryl hydrocarbon receptor signaling and expression levels of multidrug resistance genes in head and neck squamous cell carcinoma cell lines but does not change the potency of antineoplastic drugs. (2025) Toxicology and Applied Pharmacology, 117443.
  • NewsRx. Heidelberg University Reports Findings in Head and Neck Cancer (Kynurenine enhances aryl hydrocarbon receptor signaling and expression levels of multidrug resistance genes in head and neck squamous cell carcinoma cell lines but does not change ...). Chemicals & Chemistry. July 4, 2025; p 1151.

Read more